Simon Barry J.

SEC source: 0001326110-26-000085 · wk-form4_1791324382.xml · nonDerivative · entry 1

Simon Barry J. · CIK 0001647994 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 2,777,788

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 18, 2025.

F2 · price: Represents the weighted average share price of an aggregate total of 25,000 shares sold in the price range of $10.665 to $10.78 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, ImmunityBio, Inc. (the "Issuer") or a security holder of the Issuer, full information regarding the number of shares sold at each separate price.

SEC source: 0001647994-26-000011 · wk-form4_1782522004.xml · nonDerivative · entry 1

Simon Barry J. · CIK 0001647994 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 2,802,788

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 18, 2025.

F2 · price: Represents the weighted average share price of an aggregate total of 25,000 shares sold in the price range of $7.875 to $7.885 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, ImmunityBio, Inc. (the "Issuer") or a security holder of the Issuer, full information regarding the number of shares sold at each separate price.

SEC source: 0001647994-26-000008 · wk-form4_1780694977.xml · nonDerivative · entry 1

Simon Barry J. · CIK 0001647994 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 2,827,788

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 18, 2025.

F2 · price: Represents the weighted average share price of an aggregate total of 23,033 shares sold in the price range of $7.125 to $7.225 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, ImmunityBio, Inc. (the "Issuer") or a security holder of the Issuer, full information regarding the number of shares sold at each separate price.

SEC source: 0001647994-26-000006 · wk-form4_1772154743.xml · nonDerivative · entry 1

Simon Barry J. · CIK 0001647994 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 2,850,821

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 4, 2024.

F2 · price: Represents the weighted average share price of an aggregate total of 75,000 shares sold in the price range of $12.00 to $12.025 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, ImmunityBio, Inc. (the "Issuer") or a security holder of the Issuer, full information regarding the number of shares sold at each separate price.

SEC source: 0001647994-26-000004 · wk-form4_1771981423.xml · nonDerivative · entry 4

Simon Barry J. · CIK 0001647994 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 2,925,821

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 4, 2024.

F4 · price: Represents the weighted average share price of an aggregate total of 165,000 shares sold in the price range of $9.89 to $10.635 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

SEC source: 0001647994-26-000004 · wk-form4_1771981423.xml · derivative · entry 5

Simon Barry J. · CIK 0001647994 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 15,245

Underlying: Common Stock · 15,243 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of ImmunityBio, Inc. (the "Issuer") common stock.

F5 · derivative.exercise_date: Subject to the reporting person's continuing to be a Service Provider (as defined in the Issuer's Amended and Restated 2015 Equity Incentive Plan) through each applicable vesting date, 33.33% of the shares subject to the RSU award shall vest in equal annual installments on each of the first and second anniversaries of the vesting commencement date and 33.34% of the shares subject to the RSU award shall vest on the third anniversary of the vesting commencement date, such that all shares shall be fully vested on the third anniversary of the vesting commencement date. The vesting commencement date for this RSU award is February 22, 2024.

F5 · derivative.expiration_date: Subject to the reporting person's continuing to be a Service Provider (as defined in the Issuer's Amended and Restated 2015 Equity Incentive Plan) through each applicable vesting date, 33.33% of the shares subject to the RSU award shall vest in equal annual installments on each of the first and second anniversaries of the vesting commencement date and 33.34% of the shares subject to the RSU award shall vest on the third anniversary of the vesting commencement date, such that all shares shall be fully vested on the third anniversary of the vesting commencement date. The vesting commencement date for this RSU award is February 22, 2024.

SEC source: 0001647994-26-000004 · wk-form4_1771981423.xml · nonDerivative · entry 3

Simon Barry J. · CIK 0001647994 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 3,090,821

F3 · price: On February 22, 2026, the Reporting Person's RSUs vested. The closing price of Immunity Bio, Inc.'s common stock on February 20, 2026 was the settlement price used to calculate the shares withheld.

SEC source: 0001647994-26-000004 · wk-form4_1771981423.xml · nonDerivative · entry 2

Simon Barry J. · CIK 0001647994 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 3,096,847

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · security: Each restricted stock unit ("RSU") represents a contingent right to receive one share of ImmunityBio, Inc. (the "Issuer") common stock.

SEC source: 0001647994-26-000004 · wk-form4_1771981423.xml · nonDerivative · entry 1

Simon Barry J. · CIK 0001647994 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 3,081,604

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 4, 2024.

SEC source: 0001647994-26-000002 · wk-form4_1769045681.xml · nonDerivative · entry 2

Simon Barry J. · CIK 0001647994 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 3,091,604

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 4, 2024.

F2 · price: Represents the weighted average share price of an aggregate total of 75,000 shares sold in the price range of $7.87 to $7.8950 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

SEC source: 0001647994-26-000002 · wk-form4_1769045681.xml · nonDerivative · entry 1

Simon Barry J. · CIK 0001647994 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 3,166,604

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 4, 2024.

SEC source: 0001326110-25-000020 · wk-form4_1740535859.xml · derivative · entry 3

Simon Barry J. · CIK 0001647994 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 30,488

Underlying: Common Stock · 15,243 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of ImmunityBio, Inc. (the "Issuer") common stock.

F3 · derivative.exercise_date: Subject to the reporting person's continuing to be a Service Provider (as defined in the Issuer's Amended and Restated 2015 Equity Incentive Plan) through each applicable vesting date, 33.33% of the shares subject to the RSU award shall vest in equal annual installments on each of the first and second anniversaries of the vesting commencement date and 33.34% of the shares subject to the RSU award shall vest on the third anniversary of the vesting commencement date, such that all shares shall be fully vested on the third anniversary of the vesting commencement date. The vesting commencement date for this RSU award is February 22, 2024.

F3 · derivative.expiration_date: Subject to the reporting person's continuing to be a Service Provider (as defined in the Issuer's Amended and Restated 2015 Equity Incentive Plan) through each applicable vesting date, 33.33% of the shares subject to the RSU award shall vest in equal annual installments on each of the first and second anniversaries of the vesting commencement date and 33.34% of the shares subject to the RSU award shall vest on the third anniversary of the vesting commencement date, such that all shares shall be fully vested on the third anniversary of the vesting commencement date. The vesting commencement date for this RSU award is February 22, 2024.

SEC source: 0001326110-25-000020 · wk-form4_1740535859.xml · nonDerivative · entry 2

Simon Barry J. · CIK 0001647994 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,243,571

F2 · price: On February 22, 2025, the Reporting Person's RSUs vested. The closing price of Immunity Bio, Inc.'s common stock on February 21, 2025 was the settlement price used to calculate the shares withheld.

SEC source: 0001326110-25-000020 · wk-form4_1740535859.xml · nonDerivative · entry 1

Simon Barry J. · CIK 0001647994 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,249,024

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: Each restricted stock unit ("RSU") represents a contingent right to receive one share of ImmunityBio, Inc. (the "Issuer") common stock.

SEC source: 0001326110-25-000006 · wk-form4_1737769665.xml · derivative · entry 2

Simon Barry J. · CIK 0001647994 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 110,020 shares

Expires 2025-02-16

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Cash exercise of options scheduled to expire on February 16, 2025.

F2 · derivative.exercise_date: Subject to the reporting person's continuing service, one twenty-fourth (1/24th) of the shares subject to the option vested each month on the same day as the vesting commencement date, such that the shares subject to the option became fully vested and exercisable on the second (2nd) anniversary of the vesting commencement date. The vesting commencement date for this option was January 16, 2015.

SEC source: 0001326110-25-000006 · wk-form4_1737769665.xml · nonDerivative · entry 1

Simon Barry J. · CIK 0001647994 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,233,781

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Cash exercise of options scheduled to expire on February 16, 2025.

SEC source: 0000950170-24-076997 · ownership.xml · derivative · entry 1

Simon Barry J. · CIK 0001647994 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 50,000

Underlying: Common Stock · 50,000 shares

Expires 2034-06-20

F1 · derivative.exercise_date: 1/12th of the shares subject to the option shall vest each month following the date of grant, or if earlier 100% of the shares subject to the option shall vest on the date of the Issuer's next annual stockholder meeting, in each case subject to the reporting person remaining a Service Provider (as defined in the 2021 Equity Incentive Plan) through the applicable vesting date.

SEC source: 0001326110-24-000028 · wk-form4_1708983764.xml · derivative · entry 2

Simon Barry J. · CIK 0001647994 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 159,146

Underlying: Common Stock · 159,146 shares

Expires 2034-02-22

F3 · derivative.exercise_date: Subject to the reporting person's continuing to be a Service Provider (as defined in the Issuer's Amended and Restated 2015 Equity Incentive Plan) through each applicable vesting date, 33.33% of the shares subject to the option shall vest in equal annual installments on each of the first and second anniversaries of the vesting commencement date and 33.34% of the shares subject to the option shall vest on the third anniversary of the vesting commencement date, such that all shares shall be fully vested on the third anniversary of the vesting commencement date. The vesting commencement date for this option is February 22, 2024.

SEC source: 0001326110-24-000028 · wk-form4_1708983764.xml · derivative · entry 1

Simon Barry J. · CIK 0001647994 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 45,731

Underlying: Common Stock · 45,731 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of ImmunityBio, Inc. (the "Issuer") common stock.

F2 · derivative.exercise_date: Subject to the reporting person's continuing to be a Service Provider (as defined in the Issuer's Amended and Restated 2015 Equity Incentive Plan) through each applicable vesting date, 33.33% of the shares subject to the RSU award shall vest in equal annual installments on each of the first and second anniversaries of the vesting commencement date and 33.34% of the shares subject to the RSU award shall vest on the third anniversary of the vesting commencement date, such that all shares shall be fully vested on the third anniversary of the vesting commencement date. The vesting commencement date for this RSU award is February 22, 2024.

F2 · derivative.expiration_date: Subject to the reporting person's continuing to be a Service Provider (as defined in the Issuer's Amended and Restated 2015 Equity Incentive Plan) through each applicable vesting date, 33.33% of the shares subject to the RSU award shall vest in equal annual installments on each of the first and second anniversaries of the vesting commencement date and 33.34% of the shares subject to the RSU award shall vest on the third anniversary of the vesting commencement date, such that all shares shall be fully vested on the third anniversary of the vesting commencement date. The vesting commencement date for this RSU award is February 22, 2024.

SEC source: 0001326110-24-000015 · wk-form4_1706920709.xml · derivative · entry 3

Simon Barry J. · CIK 0001647994 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 57,200 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of ImmunityBio, Inc. common stock.

F2 · derivative.exercise_date: Subject to the reporting person's continuing to be a Service Provider (as defined in the Amended and Restated 2015 Equity Incentive Plan) through each applicable vesting date, 57,199 of the RSUs subject to the award vested on September 1, 2023 and 57,200 of the RSUs subject to the award vested on January 31, 2024.

F2 · derivative.expiration_date: Subject to the reporting person's continuing to be a Service Provider (as defined in the Amended and Restated 2015 Equity Incentive Plan) through each applicable vesting date, 57,199 of the RSUs subject to the award vested on September 1, 2023 and 57,200 of the RSUs subject to the award vested on January 31, 2024.

SEC source: 0001326110-24-000015 · wk-form4_1706920709.xml · nonDerivative · entry 2

Simon Barry J. · CIK 0001647994 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,123,761

SEC source: 0001326110-24-000015 · wk-form4_1706920709.xml · nonDerivative · entry 1

Simon Barry J. · CIK 0001647994 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,145,855

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001326110-23-000113 · wk-form4_1694043530.xml · derivative · entry 2

Simon Barry J. · CIK 0001647994 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 57,200

Underlying: Common Stock · 57,199 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of ImmunityBio, Inc. common stock.

F2 · derivative.exercise_date: Subject to the reporting person's continuing to be a Service Provider (as defined in the Amended and Restated 2015 Equity Incentive Plan) through each applicable vesting date, 57,199 of the RSUs subject to the award vested on September 1, 2023 and 57,200 of the RSUs subject to the award shall vest on January 31, 2024.

F2 · derivative.expiration_date: Subject to the reporting person's continuing to be a Service Provider (as defined in the Amended and Restated 2015 Equity Incentive Plan) through each applicable vesting date, 57,199 of the RSUs subject to the award vested on September 1, 2023 and 57,200 of the RSUs subject to the award shall vest on January 31, 2024.

SEC source: 0001326110-23-000113 · wk-form4_1694043530.xml · nonDerivative · entry 1

Simon Barry J. · CIK 0001647994 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,088,655

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001326110-23-000108 · wk-form4_1693270861.xml · derivative · entry 1

Simon Barry J. · CIK 0001647994 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 114,399

Underlying: Common Stock · 114,399 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of ImmunityBio, Inc. common stock.

F2 · derivative.exercise_date: Subject to the reporting person's continuing to be a Service Provider (as defined in the Amended and Restated 2015 Equity Incentive Plan) through each applicable vesting date, 57,199 of the RSUs subject to the award shall vest on September 1, 2023 and 57,200 of the RSUs subject to the award shall vest on January 31, 2024.

F2 · derivative.expiration_date: Subject to the reporting person's continuing to be a Service Provider (as defined in the Amended and Restated 2015 Equity Incentive Plan) through each applicable vesting date, 57,199 of the RSUs subject to the award shall vest on September 1, 2023 and 57,200 of the RSUs subject to the award shall vest on January 31, 2024.

SEC source: 0001209191-23-036041 · doc4.xml · derivative · entry 1

Simon Barry J. · CIK 0001647994 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 40,000

Underlying: Common Stock · 40,000 shares

Expires 2033-06-08

F1 · derivative.exercise_date: 1/12th of the shares subject to the option shall vest each month following the date of grant, or if earlier 100% of the shares subject to the option shall vest on the date of the Issuer's next annual stockholder meeting, in each case subject to the reporting person remaining a Service Provider (as defined in the 2021 Equity Incentive Plan) through the applicable vesting date.

SEC source: 0001209191-22-036018 · doc4.xml · derivative · entry 1

Simon Barry J. · CIK 0001647994 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 40,000

Underlying: Common Stock · 40,000 shares

Expires 2032-06-09

F1 · derivative.exercise_date: 1/12th of the shares subject to the option shall vest each month following the date of grant, or if earlier 100% of the shares subject to the option shall vest on the date of the Issuer's next annual stockholder meeting, in each case subject to the reporting person remaining a Service Provider (as defined in the 2021 Equity Incentive Plan) through the applicable vesting date.

SEC source: 0001326110-22-000022 · wf-form4_164825672604822.xml · derivative · entry 1

Simon Barry J. · CIK 0001647994 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,714

Underlying: Common Stock · 10,714 shares

Expires 2032-03-23

F1 · derivative.exercise_date: Subject to the reporting person's continuing to be a Service Provider (as defined in the Amended and Restated 2015 Equity Incentive Plan) through each applicable vesting date, one-third (1/3rd) of the shares subject to the option shall vest in equal annual installments on each of the first, second and third anniversaries of the vesting commencement date, such that all shares shall be fully vested on the third anniversary of the vesting commencement date. The vesting commencement date for this option is March 23, 2022.

SEC source: 0001326110-22-000003 · wf-form5_164340529573345.xml · nonDerivative · entry 1

Simon Barry J. · CIK 0001647994 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,031,456

SEC source: 0001209191-21-035815 · doc4.xml · nonDerivative · entry 3

Simon Barry J. · CIK 0001647994 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,102,507

F3 · price: Represents the weighted average share price of an aggregate total of 88,787 shares sold in the price range of $16.00 to $16.425 by the reporting person. The reporting person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

SEC source: 0001209191-21-035815 · doc4.xml · nonDerivative · entry 2

Simon Barry J. · CIK 0001647994 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,191,294

F2 · price: Represents the weighted average share price of an aggregate total of 21,223 shares sold in the price range of $16.00 to $16.115 by the reporting person. The reporting person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

SEC source: 0001209191-21-035815 · doc4.xml · nonDerivative · entry 1

Simon Barry J. · CIK 0001647994 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,212,517

F1 · price: Represents the weighted average share price of an aggregate total of 14,990 shares sold in the price range of $16.00 to $16.26 by the reporting person. The reporting person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

SEC source: 0001209191-21-030886 · doc4.xml · derivative · entry 2

Simon Barry J. · CIK 0001647994 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 56,967 shares

Expires 2024-12-18

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: Subject to the reporting person's continuing service, one twenty-fourth (1/24th) of the shares subject to the option shall vest each month on the same day as the vesting commencement date, such that the shares subject to the option shall become fully vested and exercisable on the second (2nd) anniversary of the vesting commencement date. The vesting commencement date for this option is December 18, 2014. The option originally covered 200,000 pre 1.8515 for 1 forward split shares. Pursuant to the reporting person's employment agreement, the shares subject to the option shall be subject to certain accelerated vesting and post-termination exercise period provisions upon certain events.

SEC source: 0001209191-21-030886 · doc4.xml · nonDerivative · entry 1

Simon Barry J. · CIK 0001647994 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,227,507

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001209191-21-023661 · doc4.xml · derivative · entry 1

Simon Barry J. · CIK 0001647994 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 80,000

Underlying: Common Stock · 80,000 shares

Expires 2031-03-26

F1 · derivative.exercise_date: One thirty-sixth (1/36th) of the Shares subject to the Option shall vest on the one (1) month anniversary of March 3, 2021 (the "Vesting Commencement Date"), and one thirty-sixth (1/36th) of the Shares subject to the Option shall vest each month thereafter on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month), subject to the reporting person continuing to be a Service Provider (as defined in the Viracta Therapeutics, Inc. 2021 Equity Incentive Plan) through each such date.

SEC source: 0001209191-21-008510 · doc4.xml · derivative · entry 3

Simon Barry J. · CIK 0001647994 · Director · See remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 110,020

Underlying: Common Stock · 22,100 shares

Expires 2025-02-16

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: Subject to the reporting person's continuing service, one twenty-fourth (1/24th) of the shares subject to the option shall vest each month on the same day as the vesting commencement date, such that the shares subject to the option shall become fully vested and exercisable on the second (2nd) anniversary of the vesting commencement date. The vesting commencement date for this option is January 16, 2015.

SEC source: 0001209191-21-008510 · doc4.xml · nonDerivative · entry 2

Simon Barry J. · CIK 0001647994 · Director · See remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,170,540

F1 · kind: The sale of shares reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on December 12, 2019.

F2 · price: Represents the weighted average share price of an aggregate total of 22,100 shares sold in the price range of $23.00 to $23.315 by the reporting person. The reporting person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

SEC source: 0001209191-21-008510 · doc4.xml · nonDerivative · entry 1

Simon Barry J. · CIK 0001647994 · Director · See remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,192,640

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001209191-21-007873 · doc4.xml · derivative · entry 3

Simon Barry J. · CIK 0001647994 · Director · See remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 132,120

Underlying: Common Stock · 82,070 shares

Expires 2025-02-16

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: Subject to the reporting person's continuing service, one twenty-fourth (1/24th) of the shares subject to the option shall vest each month on the same day as the vesting commencement date, such that the shares subject to the option shall become fully vested and exercisable on the second (2nd) anniversary of the vesting commencement date. The vesting commencement date for this option is January 16, 2015.

SEC source: 0001209191-21-007873 · doc4.xml · nonDerivative · entry 2

Simon Barry J. · CIK 0001647994 · Director · See remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,170,540

F1 · kind: The sale of shares reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on December 12, 2019.

F2 · price: Represents the weighted average share price of an aggregate total of 82,070 shares sold in the price range of $20.50 to $20.98 by the reporting person. The reporting person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

SEC source: 0001209191-21-007873 · doc4.xml · nonDerivative · entry 1

Simon Barry J. · CIK 0001647994 · Director · See remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,252,610

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001209191-21-006310 · doc4.xml · derivative · entry 6

Simon Barry J. · CIK 0001647994 · Director · See remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 214,190

Underlying: Common Stock · 11,304 shares

Expires 2025-02-16

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: Subject to the reporting person's continuing service, one twenty-fourth (1/24th) of the shares subject to the option shall vest each month on the same day as the vesting commencement date, such that the shares subject to the option shall become fully vested and exercisable on the second (2nd) anniversary of the vesting commencement date. The vesting commencement date for this option is January 16, 2015.

SEC source: 0001209191-21-006310 · doc4.xml · nonDerivative · entry 4

Simon Barry J. · CIK 0001647994 · Director · See remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,170,540

F1 · kind: The sale of shares reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on December 12, 2019.

F3 · price: Represents the weighted average share price of an aggregate total of 11,304 shares sold in the price range of $20.50 to $20.75 by the reporting person. The reporting person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

SEC source: 0001209191-21-006310 · doc4.xml · nonDerivative · entry 3

Simon Barry J. · CIK 0001647994 · Director · See remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,181,844

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001209191-21-006310 · doc4.xml · derivative · entry 5

Simon Barry J. · CIK 0001647994 · Director · See remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 225,494

Underlying: Common Stock · 36,626 shares

Expires 2025-02-16

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: Subject to the reporting person's continuing service, one twenty-fourth (1/24th) of the shares subject to the option shall vest each month on the same day as the vesting commencement date, such that the shares subject to the option shall become fully vested and exercisable on the second (2nd) anniversary of the vesting commencement date. The vesting commencement date for this option is January 16, 2015.

SEC source: 0001209191-21-006310 · doc4.xml · nonDerivative · entry 2

Simon Barry J. · CIK 0001647994 · Director · See remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,170,540

F1 · kind: The sale of shares reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on December 12, 2019.

F2 · price: Represents the weighted average share price of an aggregate total of 36,626 shares sold in the price range of $20.50 to $20.78 by the reporting person. The reporting person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

SEC source: 0001209191-21-006310 · doc4.xml · nonDerivative · entry 1

Simon Barry J. · CIK 0001647994 · Director · See remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,207,166

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000899243-21-000712 · doc4.xml · derivative · entry 1

Simon Barry J. · CIK 0001647994 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,000

Underlying: Common Stock · 10,000 shares

Expires 2031-01-03

F1 · shares: Represents a stock option award granted pursuant to the Issuer's Director Compensation Policy.

F2 · derivative.exercise_date: This option was granted on January 4, 2021. The shares underlying the option are scheduled to vest in full on the anniversary of the grant date.

SEC source: 0001209191-20-065246 · doc4.xml · derivative · entry 3

Simon Barry J. · CIK 0001647994 · Director · See remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 262,120

Underlying: Common Stock · 130,000 shares

Expires 2025-02-16

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: Subject to the reporting person's continuing service, one twenty-fourth (1/24th) of the shares subject to the option shall vest each month on the same day as the vesting commencement date, such that the shares subject to the option shall become fully vested and exercisable on the second (2nd) anniversary of the vesting commencement date. The vesting commencement date for this option is January 16, 2015.

SEC source: 0001209191-20-065246 · doc4.xml · nonDerivative · entry 2

Simon Barry J. · CIK 0001647994 · Director · See remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,170,540

F1 · kind: The sale of shares reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on December 12, 2019.

F2 · price: Represents the weighted average share price of an aggregate total of 130,000 shares sold in the price range of $18.00 to $18.245 by the reporting person. The reporting person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.